DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company operates DaVita Rx, a pharmacy that provides oral medications and medication management services to patients with ESRD; disease management services; vascular access services; clinical research programs; physician services; and direct primary care services. As of December 31, 2017, it provided dialysis and administrative services in the United States through a network of 2,510 outpatient dialysis centers serving approximately 197,800 patients; and operated 237 outpatient dialysis centers located in 11 countries outside of the United States. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was founded in 1994 and is headquartered in Denver, Colorado.
Industry, Sector and Symbol
Industry Miscellaneous health & allied services, not elsewhere classified
Sub-IndustryHealth Care Services
SectorMedical
Phone303-405-2100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$11.40 billion
Profitability
Miscellaneous
Employees74,500
Next Earnings Date5/2/2019 (Estimated)
OptionableOptionable
Davita (NYSE:DVA) Frequently Asked Questions
What is Davita's stock symbol?
Davita trades on the New York Stock Exchange (NYSE) under the ticker symbol "DVA."
How will Davita's stock buyback program work?
Davita announced that its board has authorized a share buyback program on Wednesday, October 11th 2017, which allows the company to repurchase $1,500,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to buy shares of its stock through open market purchases. Shares repurchase programs are often a sign that the company's board of directors believes its shares are undervalued.
How were Davita's earnings last quarter?
Davita Inc (NYSE:DVA) released its quarterly earnings data on Wednesday, February, 13th. The company reported $0.90 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.89 by $0.01. The firm had revenue of $2.82 billion for the quarter, compared to the consensus estimate of $2.97 billion. Davita had a return on equity of 14.17% and a net margin of 1.40%. The business's quarterly revenue was up 1.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.92 earnings per share. View Davita's Earnings History.
When is Davita's next earnings date?
What price target have analysts set for DVA?
9 equities research analysts have issued twelve-month price objectives for Davita's shares. Their forecasts range from $59.00 to $70.00. On average, they expect Davita's stock price to reach $64.5733 in the next twelve months. This suggests a possible upside of 10.0% from the stock's current price. View Analyst Price Targets for Davita.
What is the consensus analysts' recommendation for Davita?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Davita in the last year. There are currently 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Davita.
Has Davita been receiving favorable news coverage?
Media headlines about DVA stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Davita earned a daily sentiment score of 1.7 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
Who are some of Davita's key competitors?
What other stocks do shareholders of Davita own?
Who are Davita's key executives?
Davita's management team includes the folowing people:
- Mr. Kent J. Thiry, Chairman & CEO (Age 63)
- Mr. Joel Ackerman, Chief Financial Officer (Age 54)
- Mr. James K. Hilger, Chief Accounting Officer (Age 57)
- Ms. Kathleen Alyce Waters, Chief Legal Officer (Age 51)
- Mr. Javier J. Rodriguez, Chief Exec. Officer of DaVita Kidney Care (Age 48)
Who are Davita's major shareholders?
Davita's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.79%), Dimensional Fund Advisors LP (1.55%), Gates Capital Management Inc. (1.34%), Oregon Public Employees Retirement Fund (1.13%), Jarislowsky Fraser Ltd (1.11%) and Bank of New York Mellon Corp (1.10%). Company insiders that own Davita stock include Charles Berg, James K Hilger, Javier Rodriguez, Kent J Thiry, Leanne M Zumwalt, Pamela M Arway and William L Roper. View Institutional Ownership Trends for Davita.
Which institutional investors are selling Davita stock?
DVA stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Millennium Management LLC, Partner Fund Management L.P., Consulta Ltd, Bank of New York Mellon Corp, Manning & Napier Group LLC, Two Sigma Investments LP and KBC Group NV. Company insiders that have sold Davita company stock in the last year include Charles Berg, Pamela M Arway and William L Roper. View Insider Buying and Selling for Davita.
Which institutional investors are buying Davita stock?
DVA stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Oregon Public Employees Retirement Fund, DPM Capital LLC, Caption Management LLC, Gates Capital Management Inc., Toronto Dominion Bank, First Trust Advisors LP and State of Tennessee Treasury Department. View Insider Buying and Selling for Davita.
How do I buy shares of Davita?
Shares of DVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Davita's stock price today?
One share of DVA stock can currently be purchased for approximately $58.70.
How big of a company is Davita?
Davita has a market capitalization of $9.74 billion and generates $11.40 billion in revenue each year. The company earns $159.39 million in net income (profit) each year or $3.57 on an earnings per share basis. Davita employs 74,500 workers across the globe.
What is Davita's official website?
How can I contact Davita?
Davita's mailing address is 2000 16TH STREET, DENVER CO, 80202. The company can be reached via phone at 303-405-2100 or via email at [email protected]
MarketBeat Community Rating for Davita (NYSE DVA)
MarketBeat's community ratings are surveys of what our community members think about Davita and other stocks. Vote "Outperform" if you believe DVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
